Compare Innodata Inc (INOD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Zimmer Biomet Holdings Inc — how do they compare? Innodata Inc trades at $61.2 (market cap $2.10B), while Zimmer Biomet Holdings Inc trades at $89.08 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 8.1× Innodata Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Innodata Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| INOD | ZBH | |
|---|---|---|
Market Cap | $2.10B | $16.95B |
Volume | 989,493 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $121.50 | $103.98 |
52-Week Low | $34.45 | $79.58 |
Typical Hold Time | 19 Days | 89 Days |
Enterprise Value | $1.86B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Innodata (INOD) trades at $60.80, down 4.12% today amid bearish technical signals. The stock shows strong fundamentals with consistent earnings beats and robust profitability (37.74% ROE, 14.66% net margin). Recent quarterly results exceeded expectations, with Q1 2026 EPS of $0.42 beating estimates by 223%. The company is expanding into motion-capture AI and agentic reinforcement learning, positioning for growth in the AI infrastructure sector.
Despite premium valuations (P/E 47.43), INOD's strong execution and AI market positioning offer upside potential. Key risks include customer concentration and competitive pressures. Analyst consensus is bullish (66.7% buy ratings), though technical indicators suggest near-term caution with the stock trading below key resistance levels.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
